Healthcare
Syngene International Limited (syngene) Q1 FY27: Revenue at Rs. 736 Cr, Operating Ebitda at Rs. 91 Cr
Syngene International Limited (SYNGENE) reports Q1 FY27 revenue at Rs. 736 Cr, with Operating EBITDA at Rs. 91 Cr.
Syngene International Limited (NSE: SYNGENE) announced its financial results for the first quarter of FY27, revealing a revenue from operations of Rs. 736 crore, a 16% decrease compared to the same period last year. The company’s operating EBITDA stood at Rs. 91 crore, marking a significant 56% decline from the previous year’s figures. Despite these challenges, Syngene remains focused on its strategic initiatives to drive long-term growth.
Financial Performance
The company’s performance in Q1 FY27 was primarily impacted by reduced offtake from a major biologics client and forex hedge losses, partially offset by ongoing cost optimization initiatives. The operating EBITDA margin for the quarter was 12%, down from 24% in the same period last year. The net profit before exceptional items was Rs. 11 crore, a stark 99% decline from Rs. 87 crore in Q1 FY26. Post exceptional items, the net loss was Rs. 9 crore, compared to a profit of Rs. 87 crore in the previous year.
Management Commentary
Kiran Mazumdar-Shaw, Executive Chairperson of Syngene, expressed her commitment to the company’s next phase of growth. ‘Syngene has built an outstanding reputation over more than three decades, underpinned by scientific excellence, customer trust, and a culture of innovation. I look forward to working with Siddharth and his leadership team as we reposition the Company for sustainable growth, driven primarily by CDMO and AI-led advanced services,’ she said.
Siddharth Mittal, Managing Director and CEO, highlighted the company’s immediate priorities. ‘As I take charge of Syngene, amid headwinds that the Company is currently navigating, I look forward to working closely with the Board and our leadership team to sharpen our focus and translate our priorities into tangible business outcomes that will provide a strong foundation for long-term growth. My immediate priorities are to sharpen our commercial execution, strengthen delivery across our businesses, and build a more agile, cost-competitive organization. At the same time, we will continue to invest in CDMO, AI, innovation, and differentiated scientific capabilities that will strengthen our competitive position,’ Mittal stated.
Deepak Jain, Chief Financial Officer, provided insights into the financial performance. ‘Our performance during the quarter was primarily impacted by the lack of offtake from a major biologics client and forex hedge loss, partially offset by our ongoing cost optimization initiatives. Consequently, the operating EBITDA margin came in at 12%. We continue to maintain a strong balance sheet and financial discipline, which provides the flexibility to invest in our strategic priorities, including infrastructure, technology platforms, automation, and emerging modalities. While we expect a degrowth in the first half of the fiscal year, business momentum is expected to improve in the second half, resulting in single-digit revenue degrowth in rupee terms for the full year and EBITDA margins in the mid-20s,’ Jain added.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Syngene International Limited
Syngene International Limited belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.
Syngene falls 11.4% over three months and has not found a floor yet. Thin margins at 8.5% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock sits at 10% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 5.4% CAGR — a respectable pace. However, the stock drops 11.4% in three months without an obvious fundamental trigger. Sector-wide pressure or a valuation re-rating can persist for longer than expected. Therefore, there is no rush to step in. Check Fundamentals of Syngene International Limited.
ALIVUS
Alivus Life Sciences Limited (alivus) Q2fy27: Revenue Up 16.0% Yoy, Ebitda Margin at Record High
Alivus Life Sciences Limited (NSE: ALIVUS) announced Q2FY27 results with 16.0% YoY revenue growth, EBITDA margin at 41.8%, and strong cash flow.
Alivus Life Sciences Limited (NSE: ALIVUS) announced its financial results for the second quarter and half-year ended September 30, 2026, showcasing a robust performance. Revenue from operations for Q2FY27 came at Rs. 6,820 Mn, marking a 16.0% year-over-year growth, driven by broad-based momentum in the non-GPL business which grew at 20.8% YoY. EBITDA for Q2FY27 stood at Rs. 2,851 Mn, a growth of 47.0% YoY with margins at 41.8%, up 520 bps QoQ & 880 bps YoY, driven by favourable product mix, new launches, and the benefits of operating leverage.
Strong Financial Performance
The company generated a strong free cash flow of Rs. 2,702 Mn, leading to Cash and Cash Equivalents (including short-term investments) of Rs. 10,116 Mn as of September 30, 2026. Commenting on the company’s performance Dr. Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said, “Q2FY27 was another strong quarter for us, with revenue growing 16.0% YoY, supported by healthy demand across all key markets and robust contributions from recent launches. Non-GPL business momentum was maintained, while CDMO business saw a meaningful pick-up during the quarter. The improving business mix and greater operating efficiencies also translated into better underlying profitability. Looking ahead, our ongoing capacity expansion and healthy development pipeline give us confidence in sustaining this momentum and delivering consistent growth.”
Future Outlook
Tushar Mistry, CFO, Alivus Life Sciences Limited said, “We delivered a strong financial performance in Q2FY27, with healthy revenue growth, improved profitability and robust cash generation. Revenue grew 16.0% YoY, supported by a favourable product mix. Healthy operating performance translated into strong cash generation, with cash flow from operations of Rs. 270 crores during H1FY27. With cash and cash equivalents of Rs. 1,012 crores as of September 30, 2026, we have ample financial flexibility to support our growth initiatives while maintaining a healthy, debt-free balance sheet. Going forward, we remain focused on sustaining profitable growth, maintaining financial discipline and creating long-term value.”
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Alivus Life Sciences Limited
Alivus Life Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Alivus gains 15.6% over three months and trades near its 52-week highs. The PEG stands at 4.11 — severely stretched. Any earnings miss could trigger a sharp de-rating. Margins at 23.3% are impressive but need to be sustained — any compression would be a red flag. The stock gives back 4.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 15.6% in three months on 6.9% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Alivus Life Sciences Limited.
Drug Manufacturers - General
Sanofi India Limited Board Meeting Concludes at 4:45 P.m. on October 29, 2026
Sanofi India Limited’s board meeting concluded at 4:45 p.m. on October 29, 2026, with significant focus on strategic initiatives.
Sanofi India Limited’s board meeting commenced at 2:30 p.m. and concluded at 4:45 p.m. on October 29, 2026. The meeting focused on strategic initiatives and operational updates, underscoring the company’s commitment to innovation and growth in the pharmaceutical sector.
Strategic Initiatives
The board deliberated on several strategic initiatives aimed at expanding market reach and enhancing product portfolios. Notably, the meeting highlighted plans to strengthen partnerships in the cardiovascular and diabetes segments, which are pivotal to the company’s growth strategy.
Operational Updates
The meeting also provided updates on operational efficiencies and cost management. The board reviewed measures taken to improve gross margins and operational efficiencies, which have contributed to the company’s robust financial performance.
Future Outlook
As a result of these strategic discussions and operational reviews, Sanofi India Limited is poised to continue its momentum in the pharmaceutical industry, focusing on sustainable long-term value creation and market leadership.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Sanofi India Limited
Sanofi India Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.
Sanofi falls 13.8% over three months and has not found a floor yet. D/E of 0.00 and a 4.16% dividend yield give the balance sheet a decent cushion. The 4.16% dividend yield is about the only thing keeping income investors interested right now. The stock sits at 2% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at -12.6% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Sanofi India Limited.
Healthcare
Strides Pharma Science Limited (star) Q2fy27: Revenue Up 17% Yoy, Ex-us Markets Growth at 31% Yoy
Strides Pharma Science Limited (STAR) reports Q2FY27 revenue at ₹14,297m, up 17% YoY; Ex-US Markets growth at 31% YoY.
Strides Pharma Science Limited (STAR) announced its consolidated financial results for the quarter (Q2FY27) and half year (H1FY27) ended 30 September 2026, showcasing a strong performance. The company reported a revenue of ₹14,297 million, marking a 17% year-on-year growth, driven by a robust 31% YoY increase in the Ex-US Markets. The US business also saw a 9% YoY growth to ₹6,855 million. EBITDA rose to ₹2,509 million, crossing the ₹2,500 million mark for the first time, despite higher input material and freight costs.
Financial Highlights
The company’s operational PAT increased by 11.5% YoY to ₹1,358 million, while the reported PAT rose 2% YoY to ₹1,341 million. The operational EPS stood at ₹14.7, up from ₹13.2. The company’s diversification strategy is evident as the Ex-US Markets surpassed the US business in quarterly revenue for the first time. The company remains focused on mitigating cost pressures through continuous optimization initiatives.
Looking Ahead
Despite the dynamic external environment, Strides Pharma Science Limited is committed to delivering sustainable and profitable growth. The company expects the Net Debt to EBITDA ratio to stabilize by the end of the year. With new board member Mr. Biren Gabhawala, the company aims to strengthen its governance and oversight mechanisms.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Strides Pharma Science Limited
Strides Pharma Science Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Strides moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. No meaningful dividend — total return is entirely dependent on capital appreciation. Buyers show up with 1.6x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises -2.8% in three months on 8.7% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Strides Pharma Science Limited.
-
KFINTECH3 days agoKfin Technologies Limited Q2fy27: Strong Performance Driven by Broad-based Revenue Growth and Margin Expansion
-
Consumer Cyclical2 days agoSky GOLD and Diamonds Limited (NSE: Skygold) Q2 and H1 FY27: Revenue at Rs 4,403.45 Crore, PAT Up 111.9%
-
AWL2 days agoAwl Agri Business Limited (AWL) Delivers Strong Q2 FY27 Growth; Revenue Grows 26% to INR 22,202 Crore with Operating Ebitda Up 11% Yoy
-
DYCL2 days agoDynamic Cables Limited (dycl) Scaling with Strength: Q2 FY27 Results Show Strong Growth
-
Industrials2 days agoNavkar Corporation Limited Announces Q2 FY27 Results: Revenue Up 15%, Ebitda Surges 20%
-
Auto Parts2 days agoSchaeffler India Limited (NSE: Schaeffler) Q3 FY26: Double-digit Growth Across Domestic and Export Businesses
-
ACUTAAS2 days agoAcutaas Chemicals Limited (acutaas) Q2 & H1 FY27 Results: Revenue Up 42.7% Yoy, PAT Surges 71.4%
-
Consumer Cyclical2 days agoHuhtamaki India Limited Q3 FY26: Net Sales Surge 23.7%, EBIT Up 18%